Screener
Myriad Genetics MYGN Prenatal Health — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Myriad Genetics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Myriad Genetics’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 6:05 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000899923-26-000038
| (in millions) | Three months ended March 31, 2026 / U.S. | Three months ended March 31, 2026 / Ro W | Three months ended March 31, 2026 / Total | Three months ended March 31, 2025 / U.S. | Three months ended March 31, 2025 / Ro W | Three months ended March 31, 2025 / Total |
|---|---|---|---|---|---|---|
| Cancer Care Continuum | $106.8 | $13.4 | $120.2 | $101.4 | $14.2 | $115.6 |
| Prenatal Health | 41.9 | — | 41.9 | 49.2 | 0.1 | 49.3 |
| Mental Health | 38.3 | — | 38.3 | 31.0 | — | 31.0 |
| Total revenue | $187.0 | $13.4 | $200.4 | $181.6 | $14.3 | $195.9 |
Item 1. Financial Statements.
FAQ
- What is Myriad Genetics's prenatal health — revenue?
- Myriad Genetics (MYGN) reported prenatal health — revenue of $41.9M in Q1 2026.
- What does prenatal health — revenue mean?
- This metric represents the total revenue generated from the sale of prenatal diagnostic testing services, including non-invasive prenatal screening products. It reflects the company's market penetration and commercial success within the reproductive health and genetic screening sector. Monitoring this revenue stream helps investors assess the growth trajectory and adoption rates of the firm's prenatal diagnostic portfolio.
Ask your AI about Myriad Genetics's prenatal health — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude